Desvenlafaxine
| Clinical data | |
|---|---|
| Pronunciation | /dɛsˌvɛnləˈfæksiːn/ des-ven-lə-FAK-seen |
| Trade names | Pristiq, Desfax, Ellefore, others |
| Other names | O-desmethylvenlafaxine, WY-45233 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a608022 |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | Serotonin–norepinephrine reuptake inhibitor (SNRI) |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 80% |
| Protein binding | Low (30%) |
| Metabolism | CYP2C19, CYP3A4, (CYP2D6 is not involved) |
| Elimination half-life | 11 hours |
| Excretion | 45% excreted unchanged in urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.149.615 |
| Chemical and physical data | |
| Formula | C16H25NO2 |
| Molar mass | 263.381 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Desvenlafaxine, sold under the brand name Pristiq among others, is a medication used to treat major depressive disorder. It is an antidepressant of the serotonin–norepinephrine reuptake inhibitor (SNRI) class and is taken by mouth. It is recommended that the need for further treatment be occasionally reassessed. Studies have shown similar effectiveness compared to its parent compound venlafaxine.
Common side effects include dizziness, trouble sleeping, increased sweating, constipation, sleepiness, anxiety, and sexual problems. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that desvenlafaxine's product labeling warn of this risk. Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and high blood pressure.
Desvenlafaxine was approved for medical use in the United States in 2008. In Europe its application for use was denied in 2009, although has since been approved for Spain and Germany. In 2023, it was the 189th most commonly prescribed medication in the United States, with more than 2 million prescriptions.